Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Millennium Management LLC

Millennium Management LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 53.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 878,159 shares of the company's stock after buying an additional 305,169 shares during the period. Millennium Management LLC owned approximately 2.17% of Keros Therapeutics worth $13,901,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KROS. Barclays PLC lifted its position in shares of Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Keros Therapeutics in the fourth quarter valued at $388,000. Exchange Traded Concepts LLC purchased a new stake in Keros Therapeutics in the fourth quarter valued at $99,000. China Universal Asset Management Co. Ltd. boosted its stake in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after acquiring an additional 1,372 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock worth $171,000 after purchasing an additional 1,100 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Up 2.9%

Shares of KROS traded up $0.41 on Friday, hitting $14.57. 581,064 shares of the stock traded hands, compared to its average volume of 843,309. The firm has a market capitalization of $591.76 million, a P/E ratio of -2.80 and a beta of 1.32. The stock's 50 day moving average is $12.70 and its two-hundred day moving average is $21.23. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same quarter in the prior year, the firm posted ($1.21) earnings per share. Research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. HC Wainwright reduced their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Truist Financial decreased their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Scotiabank reduced their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $37.00.

Insider Activity at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 20.60% of the company's stock.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.